T he occurrence of new conduction abnormalities and the need for permanent pacemaker implantation (PPI) are frequent complications of transcatheter aortic valve replacement (TAVR) and may potentially jeopardize the use of this technology in a lower-risk and younger population. 1, 2 In addition to the aortic stenosis itself, it has been shown that advanced age and comorbidities such as heart failure, hypertension, and diabetes mellitus, all of which are very frequent in candidates for TAVR, are associated with a high prevalence of left bundle-branch block (LBBB) and severe bradyarrhythmias, irrespective of TAVR.
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monitoring is undertaken. However, most candidates for TAVR undergo ECG monitoring for the first time only during and immediately after the TAVR procedure.
The occurrence of new-onset atrial fibrillation (AF) after TAVR has been reported in 10% to 30% of patients. 10 It is widely known that AF is frequently paroxysmal and subclinical, and the occurrence of an embolic event might be its first manifestation. 11 As for the occurrence of conduction disorders, the high prevalence of risk factors for AF in the TAVR population may lead to a high prevalence of subclinical AF, 12 which may go undiagnosed in the absence of ECG continuous monitoring. The objectives of this study were therefore (1) to evaluate the prevalence and predictors of previously unknown paroxysmal arrhythmias (bradyarrhythmias and tachyarrhythmias) or transient conduction disorders in patients with severe aortic stenosis who are candidates for TAVR and (2) to determine the influence of detecting silent arrhythmias before TAVR on both therapy changes and the real incidence of arrhythmic events attributable to the TAVR procedure.
Methods

Study Population
A total of 435 patients with symptomatic aortic stenosis who were candidates for TAVR in 6 different centers were included. All centers but one enrolled consecutive patients into the study. Patients were eligible for TAVR if they were considered to be at high or prohibitive surgical risk as evaluated by the heart team composed of interventional cardiologists and cardiac surgeons. TAVR procedures were performed with the use of both balloon-and self-expanding valves, as reported previously. 13 The approach was selected according to the suitability of iliofemoral access, calcification and disease of ascending aorta, proximity of previous left internal mammary artery graft to the sternum, and operators' expertise. Echocardiographic or fluoroscopy guidance was used in all procedures. Unfractionated heparin was used during all procedures, with an initial dose of 100 IU/kg, subsequently adjusted to maintain an activated clotting time ≥300s. After the procedure, anticoagulation was partially or totally reversed (protamine), and anti-vitamin K agents were started within 24 to 48 hours after the procedure in patients with an indication for chronic anticoagulation therapy. All studies were performed in accordance with the local ethics committee of each center, and all patients signed informed consent forms before the procedures. Data were prospectively entered in a dedicated database at each center.
Continuous 24-Hour ECG Monitoring
Patients were admitted to the hospital the day before the TAVR procedure. A 12-lead ECG was obtained at hospital admission, and 24-hour continuous ECG monitoring was performed thereafter. ECG monitoring was performed by means of telemetry systems with constant surveillance by trained nurses or Holter monitors 14 in 407 (93.4%) and 28 patients (6.4%), respectively. The occurrence of symptoms during arrhythmic events was assessed. All events were recorded, and telemetry strips were further analyzed by a cardiologist at each center.
All TAVR procedures were performed with ECG monitoring, and arrhythmic events were prospectively collected. Patients were on continuous ECG monitoring at least 72 hours after TAVR, 15 and an ECG was performed daily until hospital discharge. Physicians in charge of patients were aware of the ECG monitoring findings and were responsible for the changes in treatment if warranted. PPI was indicated if third-degree or advanced second-degree atrioventricular block (AVB) at any anatomic level occurred and was not expected to resolve or in the presence of sinus node dysfunction and documented symptomatic bradycardia, according to current recommendations. 16 The indication for and duration of anticoagulation therapy in newly detected AF were left to the discretion of the physician responsible for the patient.
Definitions
Paroxysmal AF was defined as any irregular atrial rhythm with absence of consistent P waves, and atrial tachycardia (AT) was defined as a period of sudden rapid and regular atrial rhythm with identifiable P waves. 17 Nonsustained ventricular tachycardia (VT) was defined as runs of ≥3 ventricular beats at a heart rate of >100 bpm lasting <30 seconds. 18 When ventricular runs lasted ≥30 seconds, it was classified as sustained VT. 18 Advanced AVB was defined as 2:1 second-degree or higher AVB.
14 Severe bradycardia was defined as heart rate <40 bpm. 16 New-onset persistent left bundle-branch block (NOP-LBBB) was defined as a new-onset LBBB after TAVR that persisted at hospital discharge. Thirty-day clinical events were defined according to the Valve Academic Research Consortium-2. 
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Statistical Analysis
Results
Baseline Characteristics
Baseline clinical and echocardiographic characteristics of the study population are shown in Table 1 . Overall, 62 patients (14.3%) had a permanent pacemaker before TAVR, and 169 patients (38.9%) had a history of paroxysmal/chronic AF/AT. Both permanent pacemaker and history of AF/AT were encountered in 36 (8.3%) of such patients.
Prevalence and Predictors of Previously Unknown Arrhythmias Before TAVR
During 24-hour ECG monitoring before TAVR, paroxysmal arrhythmias or transient conduction disorders were encountered in 102 patients (23.4%) and were classified as follows: paroxysmal AF/AT in 59 patients (13.6%), advanced AVB or severe bradycardia in 24 patients (5.5%), and sustained or nonsustained VT in 27 patients (6.2%). Of these, the arrhythmic events had been previously diagnosed in 32 patients (31.3%), and newly diagnosed arrhythmias were detected in 70 patients (68.7%; 16.1% of the study population). The newly diagnosed arrhythmic events encountered during ECG monitoring before TAVR are shown in Table 2 . Previously unknown paroxysmal AF/AT was encountered in 28 patients (10.5% of patients without known AF/AT), advanced AVB in 12 patients (3.2% of patients without prior PPI), sinus node dysfunction/severe bradycardia in 12 patients (3.2% of patients without prior PPI), nonsustained VT in 26 patients (6.0%), and intermittent LBBB in 3 patients (0.9% of patients without preexisting LBBB or pacing). A total of 8 patients (11.4% of patients with previously unknown events) had >1 type of arrhythmia diagnosed during 24-hour ECG monitoring. The mean duration of AF/AT episodes was 2.6±5.8 hours. When only AF was considered, the mean duration of episodes was 1.9±4.2 hours. No symptoms were reported in all but 1 patient, who had shortness of breath related to paroxysmal AF episodes. A change in therapy was indicated in 30 patients (42.9%; 56.6% of patients with newly diagnosed paroxysmal AF/AT or advanced AVB or severe bradycardia): a change in medical therapy in 25 patients (35.7%) and PPI in 5 patients (7.1%; Figure 1 ). Individual characteristics of patients with newly diagnosed arrhythmia and the therapy recommended after its diagnosis are shown in Table I in the online-only Data Supplement.
Baseline clinical and echocardiographic characteristics of the study population grouped according to the occurrence of newly diagnosed arrhythmias or transient conduction disorders, previously known arrhythmias, and no arrhythmias are shown in Table 3 
Arrhythmic Events After TAVR
Procedural findings and 30-day clinical outcomes for the study population overall and according to the diagnosis of previously unknown arrhythmias during ECG monitoring before TAVR are shown in Table 4 . Most patients (>90%) in both groups received a balloon-expanding valve. No significant differences were observed in procedural characteristics between groups (P>0.4 for all). There were no differences between groups regarding 30-day mortality. A higher rate of cerebrovascular events was observed among patients with newly diagnosed arrhythmias before TAVR, although this difference was nonsignificant (5.7% versus 1.6% in the group without newly diagnosed arrhythmias; P=0.062; Figure 2A ). Among the 266 patients without known AF/AT, the rate of stroke or transient ischemic attack at 30 days was 7.1% in patients with newly diagnosed AF/AT before TAVR compared with 0.4% among patients without new episodes of AF/AT (P=0.030; Figure 2B ). The 2 patients with newly diagnosed AF/AT during 24-hour ECG monitoring who had a stroke after TAVR had not received anticoagulation therapy on the diagnosis of arrhythmia. After the detection of AF, antiarrhythmic therapy had been started in both patients, and normal sinus rhythm was observed on ECG at the time of the cerebrovascular event, which occurred 8 and 9 days after the TAVR procedures. The timing of stroke within 30 days after TAVR is shown in Figure 3A . In patients with newly diagnosed arrhythmias during ECG monitoring, 75% of strokes occurred ≥72 hours after TAVR, whereas in those patients with no newly diagnosed arrhythmias, 33% of strokes occurred ≥72 hours after the procedure (P=0.197; Figure 3B ). The rates of subacute stroke (≥72 hours after TAVR) were 4.3% and 0.6% in patients with and without newly diagnosed arrhythmia, respectively (P=0.032), and no differences were observed in the rate of strokes occurring during the first 24 hours after TAVR between the 2 groups (1.4% versus 1.1%; P=0.589). Values are expressed as n (%), mean (±SD), or median (25-75th percentile). CHADS 2 indicates stroke risk index that assigns 1 point each for any of the following: recent congestive heart failure, hypertension, age ≥75 y, and diabetes mellitus and 2 points for a history of stroke or transient ischemic attack; CHA 2 DS 2 -VASc score, cardiac failure or dysfunction (1), hypertension (1), age ≥75 y (2), age 65-74 y (1), diabetes mellitus (1), stroke, transient ischemic attack or thromboembolism (2), vascular disease (1), and female (1) A total of 125 arrhythmic events or conduction disturbances were diagnosed after TAVR, and, of these, 26 events (20.8%) had already been diagnosed during 24-hour ECG monitoring before TAVR. New-onset AF/AT after TAVR was observed in 53 patients after TAVR (12.2%; 19.9% of patients with no history of AF/AT). Previously unknown AF/AT had been encountered in 16 of these patients (30.2%) during 24-hour ECG monitoring before TAVR. Patients with newly diagnosed episodes of AF/AT before TAVR had a much higher rate of AF/AT episodes after TAVR (57.1% versus 10.4%; odds ratio, 11.50; 95% confidence interval, 5.05-26.16; P<0.001; Figure 4) . Thirty-five patients required a PPI after TAVR (8.0%; 9.5% of patients with no PPI before TAVR), and, of these, 11 patients (31.4%) had silent episodes of advanced AVB or severe bradycardia during 24-hour ECG monitoring before the procedure. In addition, PPI occurred more frequently in patients with episodes of advanced AVB/severe bradycardia during 24-hour ECG monitoring before TAVR (45.8% versus 5.8%; odds ratio, 12.64; 95% confidence interval, 5.19-30.80; P<0.001; Figure 4 ). NOP-LBBB was encountered in 37 patients after TAVR (8.5%; 10.6% of patients at risk). Of these, 3 patients (8.1%) had episodes of intermittent LBBB during 24-hour ECG monitoring, and all of them developed NOP-LBBB after TAVR (100% versus 8%; P=0.001; Figure 4 ).
Discussion
Previously unknown paroxysmal arrhythmias or transient conduction disturbances, most of them asymptomatic, were encountered in up to 16.1% of candidates for TAVR as evaluated by 24-hour ECG monitoring before the procedure. These newly diagnosed arrhythmic events led to changes in treatment in approximately half of the patients and were more frequently observed in patients with a higher CHADS score and a lower LVEF. In approximately a third of patients with episodes of AF/AT, advanced AVB, or severe bradycardia requiring PPI after TAVR, the presence of these arrhythmic events had already been diagnosed during 24-hour ECG monitoring before the procedure, leading to a significant reduction in the occurrence of arrhythmias directly attributable to the TAVR procedure. Approximately 1 of 10 patients with NOP-LBBB after TAVR had paroxysmal episodes of LBBB before the procedure. Finally, the occurrence of AF/AT during 24-hour ECG monitoring before the procedure was associated with an increased rate of cerebrovascular events after TAVR.
There is evidence supporting the frequent association between aortic stenosis and conduction disturbances, and supraventricular and ventricular arrhythmias. 3, 4, 21, 22 Several mechanisms have been proposed to explain this association: first, the deposit of calcium on the conduction system as a result of its proximity to the aortic valve complex 23 and the development of left ventricular dysfunction, both of which have been associated with the occurrence of LBBB and advanced AVB in patients with aortic stenosis; 24 second, the increase in left ventricular pressure overload leading to left ventricular hypertrophy and left atrium overload. 22 Indeed, in addition to aortic stenosis, candidates for TAVR currently usually have a high comorbidity burden, which further increases the risk of arrhythmic events and conduction disorders. [3] [4] [5] [6] [7] [8] 12, 25 In fact, and consistent with previous studies, 26-29 39% of patients included had known AF/AT, and 14.3% of them had advanced AVB or severe bradycardia with PPI before TAVR. In addition, previously unknown events were encountered in nearly 1 of 5 patients during 24-hour ECG monitoring, leading to a real prevalence of AF/AT and advanced AVB or severe bradycardia before TAVR (previously and newly diagnosed) in this study of 45% and 17%, respectively. This represents one of the highest rates of supraventricular arrhythmias ever reported in TAVR patients. [26] [27] [28] [29] It is well known that 24-hour ECG monitoring has a relatively low sensitivity in the detection of paroxysmal arrhythmias, 30, 31 and this suggests that the rate of silent arrhythmic events in TAVR candidates may be even higher. Nonetheless, no control group was available in this study, and the rate of unknown arrhythmias detected by ECG monitoring in an age-and risk-matched population without aortic stenosis might have been similar.
A lower LVEF and a higher CHADS score were associated with the occurrence of newly diagnosed arrhythmic events, attributable perhaps to a higher arrhythmia burden in these patients due to a more advanced stage of cardiac disease or a higher overall burden of disease. Previous studies have shown that the presence of left ventricular dysfunction in patients with aortic stenosis is associated with longer His-ventricular intervals 24 as well as with a higher incidence of VT and AF. 21, 32 Likewise, a higher CHADS score has been associated with a higher prevalence of AF. 33 Although the clinical impact of these previously unknown arrhythmias in TAVR candidates remains to be elucidated, short episodes of AF/AT have been associated with an increased risk of stroke in patients with implantable devices and in the overall population, 11, 34 and occurrences of ventricular arrhythmias and paroxysmal AVB have been described as predictors of sudden cardiac death and adverse cardiac events. 9, 22, 35 Interestingly, ≈1 in 10 TAVR candidates had a change in therapy related to the diagnosis of previously unknown arrhythmic events, highlighting the importance of monitoring such patients before the TAVR procedures. Whether or not early therapy in patients with paroxysmal events may be associated with a potential benefit in patients undergoing TAVR should be evaluated in future studies. In addition, the fact that no treatment was implemented in ≈50% of the patients with newly diagnosed arrhythmias suggests that more data and clear guidelines are needed for the treatment of silent arrhythmic events in this group of patients.
Preexisting AF and new-onset AF have been associated with an increased risk of stroke after TAVR, 36, 37 and the occurrence of previously unknown paroxysmal AF/AT may also be associated with an increased rate of 30-day stroke if anticoagulation therapy is not prescribed early. In fact, the occurrence of AF/AT during 24-hour ECG recording was associated with an 18-fold increase in the rate of cerebrovascular events compared with patients with no AF/AT and an almost 2-fold increase compared with patients with previously known AF/AT. Importantly, none of the patients with newly diagnosed AF and stroke had received anticoagulation therapy on the detection of the arrhythmia, despite antiarrhythmic therapy having been started. Nonetheless, although these differences were significant, these results should be interpreted with caution because of the low number of events. A total of 9 of the 10 cerebrovascular events observed in this study occurred in patients with previously known or newly diagnosed AF/AT (before TAVR). In addition, almost one third of patients with new-onset AF/AT, which has been independently associated with the occurrence of subacute cerebrovascular Values are expressed as n (%), mean (±SD), or median (25-75th percentile). CHADS 2 indicates stroke risk index that assigns 1 point each for any of the following: recent congestive heart failure, hypertension, age ≥75 y, and diabetes mellitus and 2 points for a history of stroke or transient ischemic attack; CHA 2 DS 2 -VASc score, cardiac failure or dysfunction (1), hypertension (1), age ≥75 y (2), age 65-74 y (1), diabetes mellitus (1), stroke, transient ischemic attack or thromboembolism (2), vascular disease (1), and female (1); COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; and STS-PROM, Society of Thoracic Surgeons predicted risk of mortality. *P<0.05 no arrhythmias vs newly diagnosed arrhythmias. †P<0.05 known arrhythmias vs newly diagnosed arrhythmias. Values are expressed as n (%). *According to Valve Academic Research Consortium-2: absence of procedural mortality, correct positioning of a single prosthetic heart valve into the proper anatomic location, and intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mm Hg or peak velocity <3 m/s, and no moderate or severe prosthetic valve regurgitation).
by guest on January 15, 2018 http://circ.ahajournals.org/ Downloaded from February 3, 2015 events after TAVR in previous studies, 36 had newly diagnosed AF/AT before TAVR, and therefore AF/AT would have preceded the occurrence of cerebrovascular events in those cases. The temporal sequence between the presence of AF/AT and the occurrence of cerebrovascular events makes the causal association plausible. In addition, the timing of such cerebrovascular events (after the initial 72 hours) makes the contribution of procedural aspects such as catheter manipulation or valve implantation unlikely. However, when one considers the relatively low number of events, these data should be interpreted as hypothesis generating and need to be confirmed in larger studies in the future. Likewise, the occurrence of unknown AVB might have led to an increased rate of sudden cardiac death after TAVR if it occurs after the discontinuation of ECG monitoring.
The rates of new-onset AF, PPI, and LBBB after TAVR have been reported in 10% to 30% 12% to 49%, and 18% to 65%, respectively, with wide differences across studies. 10, 38 Accordingly, ≈20%, ≈10%, and ≈11% of patients had newonset AF, PPI, and NOP-LBBB after TAVR in our study. However, approximately one third of patients with new AF/ AT or advanced AVB or severe bradycardia requiring PPI had this arrhythmia before the procedure as determined by 24-hour ECG monitoring, which means that the real incidence of these events attributable to the TAVR procedure per se would in fact be reduced by approximately a third. This may have a major impact on the evaluation of these complications with different transcatheter valve systems and highlights once again the importance of monitoring such patients before the procedure to have a more accurate idea of the real effect of transcatheter valves on the occurrence of arrhythmic events. In addition, as expected, the occurrence of AF/AT and advanced AVB or severe bradycardia during 24-hour ECG monitoring was associated with a much higher risk of suffering the arrhythmic event after the procedure. Three patients also had intermittent LBBB before TAVR, and all of them developed NOP-LBBB after the procedure. The presence of underlying disease of the conduction system might explain, at least in part, the fact that a significant proportion of these conduction disorders persist at hospital discharge, despite having appeared before valve implantation.
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Clinical Implications
The results of this study suggest that performing continuous ECG monitoring for at least 24 hours before the TAVR procedure can be useful for detecting previously unknown paroxysmal arrhythmias, such as paroxysmal AF/AT and advanced degree of AVB, and this, in turn, may translate into the implementation of specific therapies to prevent the complications associated with such arrhythmias (eg, stroke, sudden death). Because of the potential major clinical benefit without increased risks and low cost, it seems reasonable to recommend the use of ECG monitoring for at least 24 hours before TAVR procedures. In patients with newly detected arrhythmias, appropriate therapy according to current recommendations should be initiated promptly. Particularly in patients with newly diagnosed AF and high cardioembolic risk, anticoagulation therapy should probably be started (and continued indefinitely) early on the detection of the AF episode to prevent the possible occurrence of cerebrovascular events after TAVR. Nonetheless, the optimal timing for the initiation of anticoagulation therapy in such patients needs to be determined on a patient-by-patient basis according to the risk of both bleeding and thromboembolic events. In addition, this strategy may lead to a reduction in the length of hospital stays by allowing an earlier indication of definitive therapy (eg, PPI in case of advanced AVB). It would also allow us to determine the real incidence of tachyarrhythmias and bradyarrhythmias attributable to the transcatheter prosthesis and to the TAVR procedure itself, which may indeed be of major importance when newer transcatheter valve systems or new indications of TAVR (eg, lower risk, younger patients) are evaluated. However, one should interpret these recommendations while bearing in mind that it is a hypothesis-generating study regarding the association between newly diagnosed arrhythmias and cerebrovascular events, and therefore these results would need to be confirmed in larger studies.
Limitations
All centers but one enrolled consecutive patients into the study, and therefore some selection bias cannot be completely ruled out. The sensitivity of 24-hour ECG monitoring is low, and the rate of unknown events might therefore be higher than reported. Telemetry strips or Holter recorders were analyzed by different cardiologists with no centralized laboratory, and consequently variations in the interpretation of these disorders cannot be ruled out. In addition, although current recommendations for the treatment of arrhythmias were followed in all centers, the indication of therapy in patients with newly diagnosed events before and after TAVR was left to the discretion of the physician responsible for the patient, and some The results regarding the association between newly diagnosed arrhythmias and 30-day cerebrovascular events need to be interpreted with caution because of the relatively small number of events. More than 90% of patients included in this study underwent TAVR with the use of a balloon-expanding valve system, and the results of the study regarding post-TAVR arrhythmias may not be applicable to patients receiving a selfexpanding valve. Further studies will be needed in patients undergoing TAVR with a self-expanding valve system.
Conclusions
In conclusion, the occurrence of previously unknown paroxysmal arrhythmias and transient conduction disorders was very frequent in TAVR candidates and led to a significant overestimation of the real rate of new-onset AF, advanced AVB, or severe bradycardia requiring PPI and NOP-LBBB after TAVR. The occurrence of previously unknown AF/AT was associated with a higher risk for cerebrovascular events. The diagnosis of these previously unknown events may have an impact on the rate of complications and the length of hospital stay after TAVR by allowing the implementation of prophylactic measures and an early indication of definitive therapy. Nonetheless, further studies with a larger number of patients are necessary to determine the best diagnostic and therapeutic strategies in patients with arrhythmic events.
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